IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological malignancies leading to their US Food and Drug Administration (FDA) approval. However, the efficacy of CAR T cells in solid tumors is limited by tumor-induced immunosuppression, leading to the development of c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Giuffrida, Lauren, Sek, Kevin, Henderson, Melissa A., House, Imran G., Lai, Junyun, Chen, Amanda X.Y., Todd, Kirsten L., Petley, Emma V., Mardiana, Sherly, Todorovski, Izabela, Gruber, Emily, Kelly, Madison J., Solomon, Benjamin J., Vervoort, Stephin J., Johnstone, Ricky W., Parish, Ian A., Neeson, Paul J., Kats, Lev M., Darcy, Phillip K., Beavis, Paul A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7647667/
https://ncbi.nlm.nih.gov/pubmed/32735774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.07.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados